T3A

AcronymDefinition
T3AType 3 Strain Abney (gene)
T3AThe 3rd Alliance (Desert Combat online gaming clan)
References in periodicals archive ?
Table 1: Shows the number of mice and the amount of doses of different groups experience Group I (C) Group II (P) Number Dose Number Dose of mice of mice 3 Physiological 3 (50 solution mg/kg) Propolis Group III (T1) Group IV (Propolis +T1 ) Number Dose Number Dose of mice of mice 3 T1A 3 T2A (P 50 mg/ kg [right arrow] (DTIC 3.5 DTIC 3.5 mg / kg) mg /kg) 3 T3A (P 50 mg / kg + DTIC 3.5 mg / kg) 3 T4A (DTIC 3.5 mg / kg [right arrow] P 50 mg / kg) C:Control , P: Treatment with Propolis, T1:Treatment with Dacarbazine, P+T1:Treatment with Propolis & Dacarbazine 18 male mice were used in this study, which was divided into 4 main groups as follows:
The T3 haplogroup was classified into T3a and T3b sub-haplogroups by previous reports (Achilli et al., 2008; Jia et al., 2010).
Studies have showed that this classification system can predict prognosis, and 5-year survival rate of iris melanoma patients was estimated to be 100% for patients with T1 tumors, 90.4% for patients with T2 tumors, 63.6% for patients with T2a tumors and 50% for patients with iris melanomas classified as T3, T3a or T4.
INF inflammation: 0 absent, 1 = +, 2 = ++, 3 = +++; LVI lymphovascular invasion Patient Age Smoking Grade Stage years 1 <60 0 3 T1 2 >60 >10 CIS TIS 3 >60 0 3 T2 4 >60 0 3 T1 5 >60 >10 3 TA 6 >60 >10 2 TA 7 >60 >10 3 T1 8 >60 >10 3 T3A Patient Inflammation Pattern CIS LVI 1 1 nested present no 2 1 CIS present no 3 1 papillary absent no 4 1 papillary present no 5 2 papillary absent no 6 0 papillary absent no 7 2 papillary present no 8 1 nested present yes
Vital Posture Clinic Suite 104, 4600 Crowchild Trail NW Calgary, Alberta, Canada T3A 2L6 Email: drscholten@vitalposture.com Tel: 403-247-4257 [C] JCCA 2016
Radical prostatectomy for clinical stage T3a disease.
Gruplardaki olgularin patolojik evre dagilimlari Patolojik evre Grup 1 (n) (%) Grup 2 (n) (%) P TO 0 0 2 0.7 T1 16 20,2 61 15,5 T2a 7 8,8 46 12,07 T2b 22 27,8 85 223 0,631 T3a 11 13,9 47 123 T3b 15 18,9 81 212 T4 8 10.1 59 15,4 Toplam 79 100 381 100 Grup 1'deki olgulann buyak cogunlugu, %97,5'i, grade 2 ve 3 tihnore sahipken olgulann yalnaca %2,5'inde grade 1 turn& saptanmor.
Patient number Age Gender Tumor size (max) Tumor number 1 43 Female <5 mm 1 2 63 Male >5 mm 1 3 45 Male >5 mm 2 4 76 Male <5 mm 1 5 79 Male >5 mm 1 6 62 Male <5 mm 1 7 65 Male <5 mm 3 8 58 Male >5 mm 1 9 67 Male <5 mm 1 10 69 Male >5 mm 1 11 76 Male >5 mm 4 12 49 Female <5 mm 3 13 50 Female >5 mm 1 14 52 Female >5 mm 1 15 57 Male >5 mm 1 16 47 Female >5 mm 4 17 81 Male >5 mm 1 18 66 Male <5 mm 1 19 63 Male >5 mm 1 20 65 Male <5 mm 1 21 68 Male >5 mm 6 22 77 Male <5 mm 1 23 42 Male >5 mm 1 24 64 Male >5 mm 3 25 60 Male <5 mm 2 Patient number Pathology 1 TaG1 2 TaG3 3 T3b 4 T3b 5 T3b 6 T3a 7 T3 8 T3 9 T3 10 T3a 11 T3 12 T3b 13 T3 14 T3 15 T1 16 T3 17 T3b 18 T3a 19 T3a 20 T3b 21 T3a 22 T3b 23 T3a 24 T3a 25 T3b